The results of a drug that appears to slow Alzheimer's disease represent a "historic moment", experts have said.
Pharmaceutical companies Eisai and Biogen have clarified that their medication works when recommended in the early stages of the disease.
Details of the study are yet to be published, but so far it appears to slow the rate of brain degradation. However, it has done enough to excite scientists and organizations dealing with dementia.
Lecanemab is designed to destroy the clumps of toxic beta-amyloid protein that build up in the brains of people with Alzheimer's. Dozens of other drug tests have failed, leaving scientists in doubt about whether amyloid was really the problem.
1,795 volunteers in the early stages of Alzheimer's were injected with lecanemab every two weeks and underwent tests of memory and mental ability. The rate of cognitive decline was reduced by 27% over the 18-month period.
In addition, it was observed that the level of toxic protein in the brain was reduced. Side effects include brain swelling and headaches. This medicine will not work for other forms of dementia.